Plasma Protein Therapeutics Market by Product (Albumins, C1-esterase Inhibitors, Coagulation Factors), Application (Hereditary Angioedema, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder) - Global Forecast 2024-2030

Plasma Protein Therapeutics Market by Product (Albumins, C1-esterase Inhibitors, Coagulation Factors), Application (Hereditary Angioedema, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder) - Global Forecast 2024-2030

The Plasma Protein Therapeutics Market size was estimated at USD 32.55 billion in 2023 and expected to reach USD 36.19 billion in 2024, at a CAGR 11.37% to reach USD 69.18 billion by 2030.

Plasma protein therapeutics consist of medications derived from human plasma, the liquid component of the blood that contains essential proteins responsible for various functions necessary to human health. These therapeutics include an array of highly specialized treatments tailored to address a variety of medical conditions resulting from the absence or malfunctioning of specific plasma proteins. The market for plasma protein therapeutics includes developing, producing, and distributing these proteins for clinical use. Increased prevalence of autoimmune and neurological diseases, along with the increasing need for regular infusions or injections throughout the life of the patient, contribute to the growth of the plasma protein therapeutics market. Surging access and affordability of plasma protein therapies for patients also fuel the market development. The adverse effects of plasma protein therapeutics and strict regulations about handling plasma protein are restricting market growth. Increasing research and development activity related to the plasma protein presents a potential opportunity for growth in the plasma protein therapeutics market. The development of an efficient protein plasma extraction/manufacturing process is expected to create growth in the market.

Regional Insights

The plasma protein therapeutics market in the Americas is highly developing, with the United States being one of the major global markets, driven by advanced healthcare infrastructure, high patient awareness levels, and the presence of key industry players. The regulatory environment fostered by the FDA ensures stringent quality and safety standards. In South America, Brazil and Argentina are emerging as key markets for plasma protein therapeutics due to growing healthcare expenditures and awareness about plasma-derived therapies. The Asia-Pacific (APAC) region presents a growth opportunity for the plasma protein therapeutics market, attributed to rising healthcare awareness, increasing disposable incomes, and a growing aging population. China and Japan are significant markets in this region, with China investing heavily in plasma collection and fractionation capabilities. Europe has well-established healthcare systems, high-quality standards, and favorable reimbursement policies. The need for immunoglobulins remains robust, and European countries are significant exporters of plasma products. The Gulf Cooperation Council (GCC) countries demonstrate a rising need for plasma protein therapeutics due to economic prosperity and increased healthcare spending. Conversely, Africa faces considerable hurdles in healthcare infrastructure and treatment access, although the interest in plasma-derived medicinal products is growing.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Plasma Protein Therapeutics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increased Prevalence of Autoimmune and Neurological Diseases
    • Need for Regular Infusions or Injections Throughout the Life of the Patient
    • Surging Access and Affordability of Plasma Protein Therapies for Patients
    • Market Restraints
      • Adverse Effects of Plasma Protein Therapeutics
      • Market Opportunities
        • Increasing Research and Development Activity Related to the Plasma Protein
        • Development of Efficient Protein Plasma Extraction/Manufacturing Process
        • Market Challenges
          • Strict Regulations Pertaining to Handling of Plasma Protein
          • Market Segmentation Analysis
            • Product: Rising usage of C1-esterase inhibitors to control and prevent the swelling attacks associated with HAE
            • Application: Growing application of plasma protein therapeutics in the secondary immunodeficiency due to prevalence of cancer and autoimmune diseases
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Plasma Protein Therapeutics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Plasma Protein Therapeutics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • GC Biopharma's groundbreaking for the plasma fractionation plant in Indonesia
              
              GC Biopharma Corp inaugurated a plasma fractionation facility at the Jababeka Industrial Estate in Indonesia. This initiative builds on GC Biopharma's distinguished global plasma product plant construction record, with successful deployments in Thailand, China, and Canada.
              
              PlasmaGen Biosciences Opens New, State-of-the-Art Manufacturing Facility for Blood Plasma Products in Kolar, Bengaluru
              
              PlasmaGen Biosciences inaugurated its advanced blood plasma-derived therapeutics manufacturing plant in Kolar, Bengaluru. The facility, which spans 8 acres, incorporates sophisticated independent but interlinked blocks designed for efficient operational workflows.
              
              Takeda to build USD 770 million plasma-derived therapy plant in Japan
              
              Takeda Pharmaceutical Company Limited announced a significant investment in the Japanese healthcare infrastructure by constructing a state-of-the-art USD 770 million facility in Osaka. This venture, which is Takeda's most substantial manufacturing capacity expansion in Japan, is set to be the plasma protein therapeutic (PDT) plant in the country.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Plasma Protein Therapeutics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Plasma Protein Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Access Biologicals LLC, ADMA Biologics, Inc., AmerisourceBergen Corporation, Baxter International Inc., Bio Products Laboratory Ltd., Bruker Corporation, China Biologic Products Holdings, Inc., CSL Limited, DiaPharma, Emergent BioSolutions, FFF Enterprises, Inc., GC Biopharma corp, Grifols, S.A., Hemarus Therapeutics Limited, KalVista Pharmaceuticals, Kamada Ltd., Kedrion S.p.A., Laboratory Corporation of America Holdings, LFB SA, Octapharma AG, Plasma Technologies, LLC, PlasmaGen BioSciences Pvt. Ltd., Reliance Industries Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific, Inc..
            
            Market Segmentation & Coverage
            
            This research report categorizes the Plasma Protein Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Product
              • Albumins
              • C1-esterase Inhibitors
              • Coagulation Factors
              • Hyperimmune Globulins
              • Immunoglobulins
              • Application
                • Hereditary Angioedema
                • Idiopathic Thrombocytopenic Purpura
                • Primary Immunodeficiency Disorder
                • Secondary Immunodeficiency
                • Region
                  • Americas
                    • Argentina
                    • Brazil
                    • Canada
                    • Mexico
                    • United States
                      • California
                      • Florida
                      • Illinois
                      • New York
                      • Ohio
                      • Pennsylvania
                      • Texas
                      • Asia-Pacific
                        • Australia
                        • China
                        • India
                        • Indonesia
                        • Japan
                        • Malaysia
                        • Philippines
                        • Singapore
                        • South Korea
                        • Taiwan
                        • Thailand
                        • Vietnam
                        • Europe, Middle East & Africa
                          • Denmark
                          • Egypt
                          • Finland
                          • France
                          • Germany
                          • Israel
                          • Italy
                          • Netherlands
                          • Nigeria
                          • Norway
                          • Poland
                          • Qatar
                          • Russia
                          • Saudi Arabia
                          • South Africa
                          • Spain
                          • Sweden
                          • Switzerland
                          • Turkey
                          • United Arab Emirates
                          • United Kingdom
                          
                          
                          Please Note: PDF & Excel + Online Access - 1 Year